Analysis
Fifty-plus rodent papers, one published human pilot (Chang 2014, n=12), one active US Phase 1 listing. The mechanism story is coherent. The human story is not yet there.
The BPC-157 file is, on paper, the strongest in the research-peptide category. More than fifty preclinical papers cover tendon-to-bone healing, gut ulceration, and crush-injury models, and the published mechanism (angiogenesis with growth-factor modulation, plus nitric-oxide system interaction) is consistent with what cell biology would predict. The catch is that the published human file is one open-label oral pilot of twelve patients in ulcerative colitis, Chang et al. 2014, and a single registered Phase 1 in the US. That gap between rodent volume and human evidence is the entire reason BPC-157 sits at #1 with a 6.8, not a 9. The methodology v1.2 weights human data at 25% precisely because we do not want a peptide with one paper in humans to outrank a compound with three Phase 2s. The 2023 FDA decision removing BPC-157 from the 503A bulk-substances list is also load-bearing here: it does not change the science but it does change the legal pathway in the US, which v1.2 captures under regulatory posture. We rate BPC-157 #1 because it is the best-documented option in a category where the bar is low, not because it is proven.
Topp fire på hver dimensjon.
Høyere er bedre. Tabulariske tall, metodikken på egen side, og ja — selgertillit teller fordi forfalskningsrisikoen er reell.
For og imot
| DET SOM FUNGERER | DET SOM IKKE FUNGERER |
|---|---|
| Largest preclinical literature of any research peptide we cover. | Single published human pilot was n=12, open-label, oral route. |
| Mechanism (angiogenesis, growth-factor modulation) is consistent with established cell biology, not back-fitted. | Most preclinical work originates from one Zagreb research program, replication from independent labs is the missing piece. |
| Two registered Phase 1 trials lifted the human-data score from a flat zero in v1.1. | FDA's 2023 503A category change closes the cleanest US compounding pathway. |
| , | Counterfeit and underdose incidents in research-channel supply. |
Testede alternativer
Tre forbindelser fra det samme sammenligningssettet.
- #2 · BUDSJETTVALG5.9TB-500Thymosin Beta-4 fragment
The actin-binding biology is real; what most online sources sell as TB-500 is a fragment, not the full thymosin beta-4 protein.
- #3 · OPPGRADERINGSVALG8.1GHK-CuCopper tripeptide
The cleanest evidence file in the database, peer-reviewed cosmetic and wound work, plus topical formulations available outside the research channel.
Kilder
3 cited- Staresinic et al. 2003, J Orthop Res
- Chang et al. 2014, Vojnosanitski Pregled
- ClinicalTrials.gov, BPC-157 listings